Otrexup Injection Launched for RA, Psoriasis
OTREXUP (methotrexate) for subcutaneous injection
Antares Pharma announced the availability of Otrexup (methotrexate for subcutaneous injection) for once-weekly self-administration with a single-dose disposable auto-injector.
Otrexup was approved by the FDA in October 2013 for use in adults with severe active rheumatoid arthritis (RA) who have had an insufficient therapeutic response to or are intolerant of an adequate trial of first line therapy including full dose non-steroidal anti-inflammatory agents (NSAIDs); and children with active polyarticular juvenile idiopathic arthritis (pJIA).
Otrexup is also indicated for use in adults who need symptomatic control of severe recalcitrant, disabling psoriasis that is not adequately responsive to other forms of therapy.
Otrexup combines methotrexate, a disease-modifying anti-rheumatic drug (DMARD), with Medi-Jet technology. This design enables patients to self-administer the drug with an integrated, shielded needle that protects against accidental needle stick and drug exposure.
Otrexup is available as a single-dose auto-injector (0.4mL) in 10mg, 15mg, 20mg, and 25mg dosage strengths in 1- and 4-count cartons.
For more information call (855) 687-3987 or visit Otrexup.com.